Methotrexate for Primary Biliary Cirrhosis: Who Is to Be Trusted?

Selmi, Carlo; Podda, Mauro

doi:10.1007/s10620-010-1435-7

Search citation statements

Order By: Relevance

Paper Sections

Select...

The Liver and Medical Therapies In Rheumatology1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The exception is provided by PBC, for which ursodeoxycholic acid (UDCA) is the only established treatment [37]. The combination of UDCA and immunosuppressants, albeit rational, failed to prove effective or sufficiently safe in most cases.…”

Section: The Liver and Medical Therapies In Rheumatologymentioning

confidence: 99%

Liver involvement in subjects with rheumatic disease

2011

Self Cite

View full text Add to dashboard Cite

The liver is often overlooked as a target organ, with pathology either secondary to an underlying disease or due to the toxicity of therapies and the medical complications of extrahepatic diseases. It is thus important for the clinical rheumatologist to be aware of the diagnostic procedure to monitor liver injury. Indeed, systemic rheumatologic diseases may be associated with liver abnormalities secondary to the presence of a coexisting autoimmune liver disease (particularly primary biliary cirrhosis or autoimmune hepatitis), the direct involvement of the liver parenchyma, or the impact of medical treatments (particularly methotrexate) on the liver. In addition, the rheumatologist should be aware of the impact of immunosuppressive agents on underlying viral infections, particularly viral hepatitis. We review herein the data on the role of the liver in the clinical management of systemic rheumatic diseases.

show abstract

Section: The Liver and Medical Therapies In Rheumatologymentioning

confidence: 99%